Rituximab for the management of idiopathic membranous nephropathy: a meta-analysis

ConclusionRituximab therapy in IMN patients can provide approximately 67% remission rate. The reduction in proteinuria was greater in patients who had higher baseline proteinuria.
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research